Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14614017 | 0.83 | USP2 (0.36) | MAPT | |
| SCHEMBL5857517 | 0.81 | DDAH1 (0.33) | DDAH1TSHR | |
| SCHEMBL27696125 | 0.78 | TSHR (0.39) | DDAH1ABCC4MAPTSLC6A2SLC6A4 | |
| SCHEMBL15698565 | 0.78 | TSHR (0.39) | DDAH1ABCC4MAPTSLC6A2SLC6A4 | |
| SCHEMBL629530 | 0.78 | TSHR (0.39) | DDAH1ABCC4MAPTSLC6A2SLC6A4 | |
| SCHEMBL20819989 | 0.77 | MAPT (0.34) | DDAH1ABCC4MAPT | |
| SCHEMBL27702751 | 0.77 | TSHR (0.38) | DDAH1ABCC4MAPTTSHR | |
| SCHEMBL22552623 | 0.77 | MAPT (0.34) | DDAH1ABCC4MAPT | |
| SCHEMBL1882200 | 0.77 | FAAH (0.37) | DDAH1ABCC4MAPTTSHR | |
| SCHEMBL6120459 | 0.77 | TSHR (0.38) | DDAH1ABCC4MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754700-A2 | Synthesis of oligoketides | Kosan Biosciences, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | ASHLEY GARY (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030092140-A1 | Novel polyketides and antibiotics | ASHLEY GARY (US) | 2003-05-15 | — | — | US | disclosed |
| US-6492562-B1 | INVENTION ALSO RELATES TO NOVEL INTERMEDIATES AND THE RESULTING MODIFIED POLYKETIDES AND ANTIBIOTICS. | KOSAN BIOSCIENCES, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1144375-A2 | SYNTHESIS OF OLIGOKETIDES | Kosan Biosciences (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044717-A9 | SYNTHESIS OF OLIGOKETIDES | — | 2001-08-23 | — | — | WO | disclosed |
| WO-2000044717-A2 | SYNTHESIS OF OLIGOKETIDES | KOSAN BIOSCIENCES, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | COASY, KARS1, ACOT7 | DDAH1 2214/4885ABCC4 3529/4885MAPT 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.